A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
rovadicitinib
Class :
JAK/ROCK inhibitor
Brand Name :
N/A
Synonyms :
rovadicitinib
Class :
JAK/ROCK inhibitor
Dosage Forms & Strengths Â
Tablet Â
5 mg Â
10 mg Â
Myeloproliferative Neoplasm (MPN) (off-label)
Currently in phase 2 clinical trial in the treatment of Myelofibrosis and also in patients with palpable splenomegaly and MPN
The dose used in the study is 5 mg four times per day or 10 mg two times a day for four weeks, which showed good therapeutic response, which was well tolerated and is safe
:
Dose Adjustments
Limited data is available
Safety and efficacy are not establishedÂ
Refer to the adult dosingÂ
Actions and Spectrum: Â
Actions: Â
Rovadicitinib, a novel oral JAK/ROCK inhibitor, triggers cell death, slows cell growth, and lowers inflammatory cytokines by targeting the JAK-STAT pathway in preclinical trials.Â
Spectrum: Â
Rovadicitinib is effective and safe for myelofibrosis patients, especially those with enlarged spleens. Â
Frequency defined Â
Platelet count reduction (17.72%) Â
Anemia (16.46%) Â
Black box warningÂ
NoneÂ
Contraindication/Caution: Â
Contraindications Â
Hypersensitivity Â
Cautions Â
Renal impairment Â
Hepatic impairment Â
Pregnancy & Breastfeeding Â
Pregnancy/lactationÂ
Pregnancy consideration:  Â
No data is available regarding the administration of the drug during pregnancy. Â
Breastfeeding warnings:  Â
No data is available regarding the excretion of drug in breast milk. Â
Pregnancy category: Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester. Â
Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    Â
Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    Â
Category N: No data is available for the drug under this category. Â
Pharmacology: Â
Rovadicitinib, a novel oral JAK/ROCK inhibitor.Â
Pharmacodynamics: Â
Rovadicitinib, a novel oral JAK/ROCK inhibitor, triggers cell death, slows cell growth, and lowers inflammatory cytokines by targeting the JAK-STAT pathway in preclinical trials.Â
Pharmacokinetics: Â
Absorption 
The AUC & peak concentrations of rovadicitinib increase with dosage.Â
Elimination and Excretion Â
The half-life is 1.3 hours Â
Administration: Â
The route of administration is oral.Â
Patient information leaflet Â
Generic Name: rovadicitinib Â
Pronounced: roh-vuh-DI-si-ti-nib Â
Why do we use rovadicitinib? Â
Rovadicitinib is undergoing phase 2 trial in China, comparing its safety and effectiveness to hydroxyurea in myelofibrosis patients.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
